These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 11699800

  • 1. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.
    James RS, Sharp WS, Bastain TM, Lee PP, Walter JM, Czarnolewski M, Castellanos FX.
    J Am Acad Child Adolesc Psychiatry; 2001 Nov; 40(11):1268-76. PubMed ID: 11699800
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 3. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.
    McCracken JT, Biederman J, Greenhill LL, Swanson JM, McGough JJ, Spencer TJ, Posner K, Wigal S, Pataki C, Zhang Y, Tulloch S.
    J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):673-83. PubMed ID: 12921475
    [Abstract] [Full Text] [Related]

  • 4. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J, Wigal SB, Spencer TJ, McGough JJ, Mays DA.
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [Abstract] [Full Text] [Related]

  • 5. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
    Faraone SV, Wigal SB, Hodgkins P.
    J Atten Disord; 2007 Jul; 11(1):74-82. PubMed ID: 17606774
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [Abstract] [Full Text] [Related]

  • 7. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting.
    Swanson J, Wigal S, Greenhill L, Browne R, Waslick B, Lerner M, Williams L, Flynn D, Agler D, Crowley KL, Fineberg E, Regino R, Baren M, Cantwell D.
    Psychopharmacol Bull; 1998 Mar; 34(1):55-60. PubMed ID: 9564199
    [Abstract] [Full Text] [Related]

  • 8. A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD.
    Greenhill LL, Swanson JM, Steinhoff K, Fried J, Posner K, Lerner M, Wigal S, Clausen SB, Zhang Y, Tulloch S.
    J Am Acad Child Adolesc Psychiatry; 2003 Oct; 42(10):1234-41. PubMed ID: 14560174
    [Abstract] [Full Text] [Related]

  • 9. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
    Pelham WE, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE.
    Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
    [Abstract] [Full Text] [Related]

  • 10. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.
    McGough JJ, Biederman J, Wigal SB, Lopez FA, McCracken JT, Spencer T, Zhang Y, Tulloch SJ.
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):530-8. PubMed ID: 15908835
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall.
    McGough JJ, Biederman J, Greenhill LL, McCracken JT, Spencer TJ, Posner K, Wigal S, Gornbein J, Tulloch S, Swanson JM.
    J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):684-91. PubMed ID: 12921476
    [Abstract] [Full Text] [Related]

  • 12. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL.
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [Abstract] [Full Text] [Related]

  • 13. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.
    Brams M, Moon E, Pucci M, López FA.
    Curr Med Res Opin; 2010 Aug; 26(8):1809-25. PubMed ID: 20491612
    [Abstract] [Full Text] [Related]

  • 14. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD.
    Brown TE, Landgraf JM.
    Postgrad Med; 2010 Sep; 122(5):42-51. PubMed ID: 20861587
    [Abstract] [Full Text] [Related]

  • 15. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
    McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E.
    J Atten Disord; 2006 Feb; 9(3):476-85. PubMed ID: 16481664
    [Abstract] [Full Text] [Related]

  • 16. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder.
    Pliszka SR, Browne RG, Olvera RL, Wynne SK.
    J Am Acad Child Adolesc Psychiatry; 2000 May; 39(5):619-26. PubMed ID: 10802980
    [Abstract] [Full Text] [Related]

  • 17. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
    Adler LA, Alperin S, Leon T, Faraone S.
    Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
    [Abstract] [Full Text] [Related]

  • 18. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 19. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
    Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL.
    Pediatrics; 1999 Dec; 104(6):1300-11. PubMed ID: 10585981
    [Abstract] [Full Text] [Related]

  • 20. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
    Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J.
    Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.